<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82496">
  <stage>Registered</stage>
  <submitdate>7/01/2008</submitdate>
  <approvaldate>7/03/2008</approvaldate>
  <actrnumber>ACTRN12608000123347</actrnumber>
  <trial_identification>
    <studytitle>Comparison of triple phase and lipid only intra-dialytic parenteral nutrition and survival and outcomes in malnourished haemodialysis patients to assess complications.</studytitle>
    <scientifictitle>Randomised blinded trial to compare triple phase and lipid only intra-dialytic parenteral nutrition in malnourished haemodialysis patients to assess survival, complications and improvements in nutrition.</scientifictitle>
    <utrn />
    <trialacronym>IDPN and nutrition in HD</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Malnourished haemodialysis patients</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Malnourished haemodialysis patients will be randomised to 1000kcal 20% lipid ClinOleic Intra-Dialytic Parenteral Nutrition (IDPN) solution given via the dialysis line during the dialysis session 3 x week for up to 3 months.</interventions>
    <comparator>1000kcal of triple phase parenteral nutrition solution containing lipid, amino acids and dextrose given via the dialysis line during the dialysis session 3 x week for up to 3 months</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>complications- survival, hyper-hypoglycaemia, fluid overload</outcome>
      <timepoint>3 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>increase in body mass using Colonial WCS-200 with Ranger 5000 weighing scales and body composition using Fresenius Body Composition Monitor H02-201-1</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>improved serum albumin using the BCP (BromoCresol Purple)method of measuring serum albumin</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>improved scored patient generated subjective global assessment (PG-SGA)</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Haemodialysis patients who had been dialyzing at Austin Health for more than 3 months will be asked to participate in the study when they present with at least 2 of the following five criteria of malnutrition
1.	Body Mass Index (BMI) &lt;20
2.	Weight loss &gt;10% in 6 months
3.	Serum albumin &lt; 30
4.	Prealbumin &lt;300mg/l
5.	normalised protein catabolic rate (nPCR) &lt;1g/kg per day</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Malignancy
Associated disease compromising 3 month survival</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Haemodialysis patients who meet the criteria will be asked to participate and on signing the consent form will be randomly allocated to treatment groups by contacting the holder of the allocation schedule "off site"</concealment>
    <sequence>Using a randomisation table from a statistic book subjects will be allocated by third party by phone on recruitment to the treatment groups</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>2 groups</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/08/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3084</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Austin Health</primarysponsorname>
    <primarysponsoraddress>Austin Health
Studley Rd 
Heidelberg VIC 3104</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Austin Health</fundingname>
      <fundingaddress>Austin Campus
Studley Rd 
Heidelberg VIC 3084</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Peter Mount</othercollaboratorname>
      <othercollaboratoraddress>Nephrology Department
Austin Health
Studley Rd
Heidelberg VIC 3084</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Several formulations have been used for IDPN and have ranged from those with minimal provision of nutrients to those that deliver significant amounts of calories and amino acids. Administration of lipid was originally considered to be contraindicated in IDPN but studies suggest otherwise and lipids are now used routinely. Austin Health is the first dialysis centre in the world to use standard lipid only IDPN solution. Since then a 20% lipid 500 ml or 30% lipid 250 ml solutions are routinely used in our haemodialysis patients requiring IDPN support. What effect if any is this practice having? Would the use of a more standardised practice of protein, lipid and dextrose combined solution be more beneficial?</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Austin Health Human Research Ethics Commitee</ethicname>
      <ethicaddress>PO Box 5000 
Heidelberg VIC 3081</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>15/01/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Karen Manley</name>
      <address>Nutrition and Dietetics Department
Studley Rd 
Heidelberg VIC 3084</address>
      <phone>+61 3 94965011</phone>
      <fax>+61 3 94963168</fax>
      <email>karen.manley@austin.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Karen Manley</name>
      <address>Nutrition and Dietetics Department
Studley Rd 
Heidelberg VIC 3084</address>
      <phone>+61 3 94965011</phone>
      <fax>+61 3 94963168</fax>
      <email>karen.manley@austin.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Karen Manley</name>
      <address>Nutrition and Dietetics Department
Studley Rd 
Heidelberg VIC 3084</address>
      <phone>+61 3 94965011</phone>
      <fax>+61 3 94963168</fax>
      <email>karen.manley@austin.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>